188 related articles for article (PubMed ID: 32642724)
41. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
42. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
43. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
44. GBM-associated mutations and altered protein expression are more common in young patients.
Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
[TBL] [Abstract][Full Text] [Related]
45. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
46. Glioblastoma: pathology, molecular mechanisms and markers.
Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
[TBL] [Abstract][Full Text] [Related]
47. Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy.
Chanez B; Appay R; Guille A; Lagarde A; Colin C; Adelaide J; Denicolai E; Jiguet-Jiglaire C; Bequet C; Graillon T; Boissonneau S; Nanni-Metellus I; Dufour H; Figarella-Branger D; Chinot O; Tabouret E
J Neurol Sci; 2022 May; 436():120207. PubMed ID: 35259554
[TBL] [Abstract][Full Text] [Related]
48. Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series.
Buccoliero AM; Giunti L; Moscardi S; Castiglione F; Provenzano A; Sardi I; Scagnet M; Genitori L; Caporalini C
Genes (Basel); 2022 Mar; 13(4):. PubMed ID: 35456430
[TBL] [Abstract][Full Text] [Related]
49. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors.
Guo X; Gu L; Li Y; Zheng Z; Chen W; Wang Y; Wang Y; Xing H; Shi Y; Liu D; Yang T; Xia Y; Li J; Wu J; Zhang K; Liang T; Wang H; Liu Q; Jin S; Qu T; Guo S; Li H; Wang Y; Ma W
Front Oncol; 2023; 13():1200815. PubMed ID: 37483487
[TBL] [Abstract][Full Text] [Related]
50. Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis.
Xie Y; Tan Y; Yang C; Zhang X; Xu C; Qiao X; Xu J; Tian S; Fang C; Kang C
Cancer Biol Med; 2019 Nov; 16(4):784-796. PubMed ID: 31908895
[TBL] [Abstract][Full Text] [Related]
51. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin.
Martinez-Diaz H; Kleinschmidt-DeMasters BK; Powell SZ; Yachnis AT
Arch Pathol Lab Med; 2003 Sep; 127(9):1187-91. PubMed ID: 12946225
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
53. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
54. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
55. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
56. Molecular Testing of Brain Tumor.
Park SH; Won J; Kim SI; Lee Y; Park CK; Kim SK; Choi SH
J Pathol Transl Med; 2017 May; 51(3):205-223. PubMed ID: 28535583
[TBL] [Abstract][Full Text] [Related]
57. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
[TBL] [Abstract][Full Text] [Related]
58. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood.
Kraus JA; Felsberg J; Tonn JC; Reifenberger G; Pietsch T
Neuropathol Appl Neurobiol; 2002 Aug; 28(4):325-33. PubMed ID: 12175345
[TBL] [Abstract][Full Text] [Related]
59. Molecular characteristics and clinical features of multifocal glioblastoma.
Dono A; Wang E; Lopez-Rivera V; Ramesh AV; Tandon N; Ballester LY; Esquenazi Y
J Neurooncol; 2020 Jun; 148(2):389-397. PubMed ID: 32440969
[TBL] [Abstract][Full Text] [Related]
60. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
